BMS is approved!

Fantastic news!! Thank you so much for posting this article!!

Maureen

Fantastic news!! Thank you so much for posting this article!!

Maureen

Fantastic news!! Thank you so much for posting this article!!

Maureen

Always great news to have another option in the arsenal.

Could someone clarify for me the following statement in the article linked above?:

 "Results showed that 32 percent of participants receiving Opdivo had their tumors shrink (objective response rate). This effect lasted for more than six months in approximately one-third of the participants who experienced tumor shrinkage."

So 1/3rd of 32% of the patients had a durable response (longer than six months)?  So roughly 11% of the patients had a durable response?  Am I doing the math right?

Always great news to have another option in the arsenal.

Could someone clarify for me the following statement in the article linked above?:

 "Results showed that 32 percent of participants receiving Opdivo had their tumors shrink (objective response rate). This effect lasted for more than six months in approximately one-third of the participants who experienced tumor shrinkage."

So 1/3rd of 32% of the patients had a durable response (longer than six months)?  So roughly 11% of the patients had a durable response?  Am I doing the math right?

Always great news to have another option in the arsenal.

Could someone clarify for me the following statement in the article linked above?:

 "Results showed that 32 percent of participants receiving Opdivo had their tumors shrink (objective response rate). This effect lasted for more than six months in approximately one-third of the participants who experienced tumor shrinkage."

So 1/3rd of 32% of the patients had a durable response (longer than six months)?  So roughly 11% of the patients had a durable response?  Am I doing the math right?

Merck's anti-PD1, Pembrolizumab, now called Keytruda and BMS's anti-PD1, Nivolumab, now called Opdivo are, per most melanoma experts – basically the same drug.  You can find one study here and another study there that puts this one over that one on particular points….but ultimately they have basically the same side effects and the same rate of response and generally efficacy.  As for as duration of response…y'all gonna have to see what happens to the ratties who took it first.  Both drugs are relatively new in human data….I began a Nivo trial in 2010, as did 32 of my fellow ratties.  10 are dead.  The rest of us are alive and kicking.  But "duration" of response takes time to ascertain.  In some ways, Opdivo has more clinical data than Keytruda.  I was hoping that Nivo/Opdivo was holding back on FDA approval because they were seeking approval as a first line drug for melanoma since they have some data to back that up.  But…that is not what materialized today.  Not what I was hoping for…but still gives more options for others, despite the required prerequisite treatments of ipi/yervoy and BRAFi…if BRAF positve. Oh, well….  what more can a rattie do?  Here is an analysis from the June ASCO reports comparing the anti-PD1 products if you're interested:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2014/07/nivoipi-combo-nivo-vs-pembro-pd-l1.html

I wish you all my best! Celeste
 

Merck's anti-PD1, Pembrolizumab, now called Keytruda and BMS's anti-PD1, Nivolumab, now called Opdivo are, per most melanoma experts – basically the same drug.  You can find one study here and another study there that puts this one over that one on particular points….but ultimately they have basically the same side effects and the same rate of response and generally efficacy.  As for as duration of response…y'all gonna have to see what happens to the ratties who took it first.  Both drugs are relatively new in human data….I began a Nivo trial in 2010, as did 32 of my fellow ratties.  10 are dead.  The rest of us are alive and kicking.  But "duration" of response takes time to ascertain.  In some ways, Opdivo has more clinical data than Keytruda.  I was hoping that Nivo/Opdivo was holding back on FDA approval because they were seeking approval as a first line drug for melanoma since they have some data to back that up.  But…that is not what materialized today.  Not what I was hoping for…but still gives more options for others, despite the required prerequisite treatments of ipi/yervoy and BRAFi…if BRAF positve. Oh, well….  what more can a rattie do?  Here is an analysis from the June ASCO reports comparing the anti-PD1 products if you're interested:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2014/07/nivoipi-combo-nivo-vs-pembro-pd-l1.html

I wish you all my best! Celeste
 

Merck's anti-PD1, Pembrolizumab, now called Keytruda and BMS's anti-PD1, Nivolumab, now called Opdivo are, per most melanoma experts – basically the same drug.  You can find one study here and another study there that puts this one over that one on particular points….but ultimately they have basically the same side effects and the same rate of response and generally efficacy.  As for as duration of response…y'all gonna have to see what happens to the ratties who took it first.  Both drugs are relatively new in human data….I began a Nivo trial in 2010, as did 32 of my fellow ratties.  10 are dead.  The rest of us are alive and kicking.  But "duration" of response takes time to ascertain.  In some ways, Opdivo has more clinical data than Keytruda.  I was hoping that Nivo/Opdivo was holding back on FDA approval because they were seeking approval as a first line drug for melanoma since they have some data to back that up.  But…that is not what materialized today.  Not what I was hoping for…but still gives more options for others, despite the required prerequisite treatments of ipi/yervoy and BRAFi…if BRAF positve. Oh, well….  what more can a rattie do?  Here is an analysis from the June ASCO reports comparing the anti-PD1 products if you're interested:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2014/07/nivoipi-combo-nivo-vs-pembro-pd-l1.html

I wish you all my best! Celeste